# Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC

> **NCT06088771** · PHASE1,PHASE2 · RECRUITING · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 21 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Dupilumab
- **BIOLOGICAL:** Cemiplimab

## Key facts

- **NCT ID:** NCT06088771
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-08
- **Primary completion:** 2026-04-15
- **Final completion:** 2027-04-22
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2025-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06088771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06088771, "Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06088771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*